- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04386239
Study on the Use of Sarilumab in Patients With COVID-19 Infection
July 19, 2021 updated by: Stefano Rusconi, ASST Fatebenefratelli Sacco
Pilot Study on the Use of Sarilumab in Patients With COVID-19 Infection
Sarilumab is an anti-interleukin-6 human monoclonal antibody, such as tocilizumab, which is administered subcutaneously every two weeks for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Despite the effectiveness reported for tocilizumab in the recently published experiences, the need to rapidly find alternative therapies to manage the complications of Covid-19 infection remains extremely high.
The lack of clinical experience on the usage of sarilumab in such patients prevents the possibility of adopting early access programs for using commercially available sarilumab (prefilled syringe) packs in patients with severe Covid-19 pneumonia.
The present study is aimed to generate a rapid, still robustly documented, evidence on the potential clinical efficacy and tolerability of a further IL-6R antagonist in Covid-19 pneumonia.
Study Overview
Detailed Description
In February 2020, the emergence of the COVID-19 epidemic in Italy and, especially, in Lombardy, with a potential fatal outcome in a significant proportion of cases, determined the need for adopting new therapeutic approached based on the few data available in literature.
Although there are no clinical data available in COVID-19 patients concomitantly treated with Sarilumab subcutaneously (SC) nor intravenously (IV), there is scientific rationale that supports the exploration of sarilumab to treat pulmonary complications related to Covid-195-6.
By inhibiting interleukin-6 (IL-6)signaling, sarilumab may potentially interrupt cytokine-mediated pulmonary injury precipitated by infection with SARS-CoV-2 and thereby ameliorate severity and/or reduce mortality among patients presenting with Covid-19 pneumonia when administered in conjunction with antiviral therapy.
given the apparent dose/dose pharmacokinetic/ pharmacodynamic (PK/PD) equivalence of 400 mg of tocilizumab to 400 mg of sarilumab, we propose a dose escalation protocol by which the first 5 included patients will be treated with a dosage of 200 mg of sarilumab IV as 1st dose, followed by clinical reassessment after 12 hours and in case of no major adverse events and lack of improvement in respiratory function and / or persistence of fever and persistently high inflammatory markers re-administration of 200 mg intravenous (IV) of sarilumab.
If no patients showed unfavorable safety signals, and no clear improvement is detected in >50% of the initially treated five patients after 96 hours since last administration, the dosage will be increase to sarilumab 400 mg IV as first and second dose in the remaining patients.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Agostino Riva, MD
- Phone Number: 02-39042676
- Email: agostino.riva@unimi.it
Study Contact Backup
- Name: Massimo Galli, Professor
- Email: massimo.galli@unimi.it
Study Locations
-
-
MI
-
Milano, MI, Italy, 20157
- Recruiting
- Divisione Clinicizzata di Malattie Infettive, ASST FBF-Sacco
-
Contact:
- Agostino Riva, M.D.
- Phone Number: 00390239042676
- Email: agostino.riva@unimi.it
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 84 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 years and < 85 years.
- Documented (chest X-Ray or TC scan), severe (BCRSS ≥3 and <4) interstitial pneumonia with respiratory failure (requiring supplemental oxygen) with positive Covid-19 swab testing.
- Worsening of respiratory exchanges such as to require ventilation with Venturi mask >31% (6L/minute).
- Increased levels of D-dimer (> 1500 ng/mL) or D-dimer progressively increasing (over 3 consecutive measurements) and reaching ≥ 1000 ng/mL.
- Signed informed consent.
Exclusion Criteria:
- Age < 18 years or ≥ 85 years.
- AST / ALT > 5x Upper normal limit.
- Neutrophil count lower than 500 cells / mL.
- Platelet count lower than 50,000 cells / mL.
- Documented sepsis due to infections other than Covid-19.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Covid-19
Patients with documented (chest X-Ray or Computed Tomography scan) Covid-19 (Polymerase Chain Reaction+ swab test) interstitial pneumonia and BCRSS ≥3 and <4 will be requested consent to the study.
|
Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients who show an improvement of the respiratory function
Time Frame: 6 weeks
|
Clinical efficacy of sarilumab in adult patients hospitalized due to severe Covid-19 pneumonia based on the proportion of patients who show an improvement of the respiratory function, described as ≥30% decrease in oxygen requirement compared to baseline (as defined as the ratio of O2 flow through the Venturi mask).
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the time to resolution of fever
Time Frame: 6 weeks
|
Evaluation of the time to resolution of fever, defined as body temperature ≤36.6°C axilla, ≤37.8°C rectal or tympanic for at least 48 hours without antipyretics in patients with fever at baseline.
|
6 weeks
|
Evaluation of the viral load on blood and sputum for COVID-19
Time Frame: Before administration of sarilumab, 48 hours and 96 hours after administration
|
Evaluation of the viral load on blood and sputum for COVID-19
|
Before administration of sarilumab, 48 hours and 96 hours after administration
|
Evaluation of the plasma concentration of GM-CSF
Time Frame: Pre-treatment and 96 and 120 hours post-treatment
|
Evaluation of the plasma concentration of GM-CSF
|
Pre-treatment and 96 and 120 hours post-treatment
|
Evaluation of the plasma concentration of Il-6
Time Frame: Pre-treatment and 96 and 120 hours post-treatment
|
Evaluation of the plasma concentration of Il-6
|
Pre-treatment and 96 and 120 hours post-treatment
|
Evaluation of the plasma concentration of TNF-α
Time Frame: Pre-treatment and 96 and 120 hours post-treatment
|
Evaluation of the plasma concentration of TNF-α
|
Pre-treatment and 96 and 120 hours post-treatment
|
Evaluation of the rate of progression of White Blood Cell (WBC) fraction
Time Frame: 96 and 120 hours post-treatment
|
Evaluation of the rate of progression of WBC fraction of immature granulocytes - IG - (absolute count).
|
96 and 120 hours post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Massimo Galli, Professor, University of Milan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2021
Primary Completion (Anticipated)
December 1, 2021
Study Completion (Anticipated)
December 1, 2021
Study Registration Dates
First Submitted
May 7, 2020
First Submitted That Met QC Criteria
May 12, 2020
First Posted (Actual)
May 13, 2020
Study Record Updates
Last Update Posted (Actual)
July 20, 2021
Last Update Submitted That Met QC Criteria
July 19, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- COVID-SARI-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Sarilumab Prefilled Syringe
-
University Hospital, ToulouseMedSharingRecruiting
-
Hospital Clínico Universitario de ValladolidUniversity of Valladolid; Complejo Asistencial Universitario de Palencia; Complejo...RecruitingBrain Diseases | Migraine Disorders | Migraine Without Aura | Migraine With AuraSpain
-
Institut RafaelActive, not recruitingPatient Satisfaction | Patient Preference | Febrile Neutropenia, Drug-InducedFrance
-
Boehringer IngelheimCompleted
-
Il-Yang Pharm. Co., Ltd.Completed
-
Il-Yang Pharm. Co., Ltd.Completed
-
Beth Israel Deaconess Medical CenterTeva Pharmaceuticals USARecruiting
-
Jonathan A. Bernstein, MDCompletedEczema | Atopic DermatitisUnited States
-
Syneos HealthDr. Reddy's Laboratories LimitedCompletedRheumatoid Arthritis | Giant Cell ArteritisNew Zealand, Australia, India
-
National Taiwan University HospitalRecruitingPre-fibrotic MyelofibrosisTaiwan